论文部分内容阅读
自1896年Beatson首次报道卵巢切除治疗晚期乳腺癌获得成功后,从此,开辟了内分泌治疗恶性肿瘤的新途径.1974年Bethesda召开的国际会议上确认激素受体含量与内分泌治疗疗效之间存在正相关后内分泌治疗乳腺癌的研究更是得到深入的发展.内分泌疗法是乳腺癌治疗的主要手段之一.它不仅用于某些晚期乳腺癌的治疗,也可用于可手术乳腺癌的辅助化疗.但内分泌疗法仅适用于激素依赖性乳腺癌,而不适用于非激素依赖性乳腺癌.ER(+)(雌激素受体阳性)者内分泌治疗有效率达50～70%,ER
Since Beatson first reported successful treatment of advanced breast cancer with ovariectomy in 1896, it has opened up new ways of endocrine therapy for malignant tumors. An international conference convened by Bethesda in 1974 confirmed a positive correlation between hormone receptor content and efficacy of endocrine therapy. The research on endocrine treatment of breast cancer is further developed. Endocrine therapy is one of the main methods for the treatment of breast cancer. It is not only used for the treatment of certain advanced breast cancer, but also can be used for adjuvant chemotherapy for operable breast cancer. Endocrine therapy is only applicable to hormone-dependent breast cancer, but not to non-hormone-dependent breast cancer. ER (+) (estrogen receptor-positive) endocrine therapy efficiency of 50 to 70%, ER